Right ventricular septal pacing: Safety and efficacy in a long term follow up

Table 1 Comparison of pre-implantation clinical features in the patient control groups (NO pacing and right ventricular apical pacing) and parahisian pacing group

	NO pacing	RVA pacing	PH pacing
Total patients	22 patients	33 patients	244 patients
Age (yr)	75 ± 7	77 ± 9	74 ± 8
Sex	13 M/9 F	21 M/12 F	169 M/ 75 F
NYHA class	1.09 ± 0.29	1.15 ± 0.36	2.13 ± 0.46
LV ejection fraction (%)	57 ± 5	55 ± 8	53 ± 11
LV end-dyastolic volume (cc)	89 ± 25	98 ± 22	100 ± 37
LV end-systolic volume (cc)	38 ± 13	47 ± 17	49 ± 27
Associated heart diseases	Ischemic heart disease: 6/22 (27%) Valvular heart disease: 2/22 (9%) Hypertensive heart disease: 2/22 (9%) No significant heart disease: 12/22 (55%)	Ischemic heart disease: 12/33 (37%) Valvular heart disease: 4/33 (12%) Hypertensive heart disease: 3/33 (9%) No significant heart disease: 14/33 (42%)	Ischemic heart disease: 80/244 (33%) Valvular heart disease: 29/244 (12%) Hypertensive heart disease: 90/244 (37%) No significant heart disease: 45/244 (18%)
Atrial fibrillation	1 (5%)	4 (12%)	132 (54%)
Sinus rhythm	21 (95%)	29 (88%)	112 (46%)

Comparison of pre-implantation clinical features in the patient control groups [NO pacing and right ventricular apical (RVA) pacing] and parahisian (PH) pacing group. NYHA: New York Heart Association; LV: Left ventricular.